{
    "2018-08-28": [
        [
            {
                "time": "",
                "original_text": "半年报数据显示：复星、中国医药营收达百亿，科伦净利迅增，泰格研发投入超销售费用",
                "features": {
                    "keywords": [
                        "半年报",
                        "复星",
                        "中国医药",
                        "科伦",
                        "泰格",
                        "营收",
                        "净利",
                        "研发投入"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：理性看待药监人事变化 积极布局估值切换行情",
                "features": {
                    "keywords": [
                        "医药行业",
                        "周报",
                        "药监",
                        "人事变化",
                        "估值切换"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【西南医药朱国广团队】同仁堂（600085）业绩增长稳定，发展潜力巨大",
                "features": {
                    "keywords": [
                        "西南医药",
                        "同仁堂",
                        "业绩增长",
                        "发展潜力"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级] 同仁堂(600085)中报点评：业绩符合预期 “品牌+品种”铸就护城河",
                "features": {
                    "keywords": [
                        "同仁堂",
                        "中报",
                        "业绩",
                        "品牌",
                        "品种",
                        "护城河"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中证报头版：青睐制造业、偏爱大蓝筹，机构二季度布局路径隐现",
                "features": {
                    "keywords": [
                        "中证报",
                        "制造业",
                        "大蓝筹",
                        "机构",
                        "二季度",
                        "布局路径"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制造业",
                        "蓝筹股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "证金二季度增持两公司 华大基因等公司披露分配预案",
                "features": {
                    "keywords": [
                        "证金",
                        "二季度",
                        "增持",
                        "华大基因",
                        "分配预案"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}